You can buy or sell RCUS and other stocks, options, ETFs, and crypto commission-free!
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. Read More The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
52 Week High
52 Week Low
Yahoo FinanceMay 9
Is Arcus Biosciences, Inc. A Good Stock To Buy?
Is Arcus Biosciences, Inc. (NYSE:RCUS) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of news stories covering failed hedge fund investments and it is a fact that hedge funds' picks don't beat the market 100% of the time, but their consensus picks have histor...
Yahoo FinanceMay 2
Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122
HAYWARD, Calif. and ANN ARBOR, Mich.--(BUSINESS WIRE)-- - Leverages Strata Oncology’s Proprietary Biomarker Technology to Stratify Patients - Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Strata Oncology, Inc. (“Strata”), a precision oncology company, today announced that the companies have entered into a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarker...
Simply Wall StApr 28
What Kind Of Shareholder Appears On The Arcus Biosciences, Inc.’s (NYSE:RCUS) Shareholder Register?
A look at the shareholders of Arcus Biosciences, Inc. (NYSE:RCUS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, ‘Don’t tell me what you think, tell me what you have in your portfolio.’ With a market capitalization of US$484m, Arcus Biosciences is a small c...
Expected Aug 6, Pre-Market